Technical Analysis for ARCT - Arcturus Therapeutics Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 26.63 | 0.30% | 0.08 |
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 0.30% | |
| Wide Bands | Range Expansion | 0.30% | |
| Oversold Stochastic | Weakness | 0.30% | |
| Doji - Bullish? | Reversal | 1.76% | |
| Stochastic Reached Oversold | Weakness | 1.76% | |
| Wide Bands | Range Expansion | 1.76% | |
| Gapped Down | Weakness | 1.76% | |
| Oversold Stochastic | Weakness | 1.76% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Possible NR7 | about 18 hours ago |
| 10 DMA Resistance | about 22 hours ago |
| Up 3% | about 22 hours ago |
| Up 2% | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/08/2024
Arcturus Therapeutics Ltd. Description
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Health Sciences Drugs Pharmacology Euphoriants Amphetamine Cognitive Disorders Glutamate Tablet Adhd Taar1 Agonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 43.81 |
| 52 Week Low | 17.5238 |
| Average Volume | 499,130 |
| 200-Day Moving Average | 29.90 |
| 50-Day Moving Average | 33.59 |
| 20-Day Moving Average | 29.28 |
| 10-Day Moving Average | 27.14 |
| Average True Range | 1.80 |
| RSI (14) | 36.71 |
| ADX | 34.54 |
| +DI | 14.87 |
| -DI | 28.43 |
| Chandelier Exit (Long, 3 ATRs) | 28.59 |
| Chandelier Exit (Short, 3 ATRs) | 30.81 |
| Upper Bollinger Bands | 34.09 |
| Lower Bollinger Band | 24.47 |
| Percent B (%b) | 0.22 |
| BandWidth | 32.86 |
| MACD Line | -2.04 |
| MACD Signal Line | -1.94 |
| MACD Histogram | -0.0996 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.26 | ||||
| Resistance 3 (R3) | 28.37 | 27.94 | 27.99 | ||
| Resistance 2 (R2) | 27.94 | 27.53 | 27.89 | 27.90 | |
| Resistance 1 (R1) | 27.29 | 27.27 | 27.07 | 27.17 | 27.81 |
| Pivot Point | 26.86 | 26.86 | 26.75 | 26.80 | 26.86 |
| Support 1 (S1) | 26.20 | 26.44 | 25.99 | 26.09 | 25.45 |
| Support 2 (S2) | 25.77 | 26.19 | 25.72 | 25.36 | |
| Support 3 (S3) | 25.12 | 25.77 | 25.27 | ||
| Support 4 (S4) | 25.00 |
